BioMarin Pharma (BMRN) Tops Q3 EPS by 23c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.46, $0.23 better than the analyst estimate of $0.23. Revenue for the quarter came in at $581.3 million versus the consensus estimate of $607.5 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.90-$2.05, versus the consensus of $2.19. BioMarin Pharma sees FY2023 revenue of $2390-2470 million, versus the consensus of $2449 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- aTyr Pharma (LIFE) Reports Q3 EPS of $0.53; Offers Guidance
- Grifols, S.A. (GRFS) Reports Q3 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
